Sivik Global Healthcare LLC Sells 2,000 Shares of Bio-Rad Laboratories, Inc. $BIO

by · The Markets Daily

Sivik Global Healthcare LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 20.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,000 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Bio-Rad Laboratories makes up about 1.9% of Sivik Global Healthcare LLC’s holdings, making the stock its 26th biggest position. Sivik Global Healthcare LLC’s holdings in Bio-Rad Laboratories were worth $3,022,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BIO. William B. Walkup & Associates Inc. boosted its holdings in shares of Bio-Rad Laboratories by 2.6% in the 1st quarter. William B. Walkup & Associates Inc. now owns 1,902 shares of the medical research company’s stock valued at $530,000 after buying an additional 48 shares in the last quarter. Cetera Investment Advisers raised its stake in Bio-Rad Laboratories by 0.6% during the 1st quarter. Cetera Investment Advisers now owns 7,596 shares of the medical research company’s stock worth $2,117,000 after acquiring an additional 48 shares in the last quarter. Rehmann Capital Advisory Group raised its stake in Bio-Rad Laboratories by 8.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 954 shares of the medical research company’s stock worth $280,000 after acquiring an additional 73 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Bio-Rad Laboratories by 2.1% in the first quarter. Oregon Public Employees Retirement Fund now owns 3,746 shares of the medical research company’s stock valued at $1,044,000 after acquiring an additional 77 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Bio-Rad Laboratories in the second quarter valued at $27,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded down $0.59 during trading on Tuesday, reaching $363.83. The company had a trading volume of 33,627 shares, compared to its average volume of 311,414. The firm has a market capitalization of $9.73 billion, a price-to-earnings ratio of 44.10 and a beta of 1.07. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.14 and a quick ratio of 2.33. The stock’s fifty day moving average price is $372.18 and its 200 day moving average price is $318.68. Bio-Rad Laboratories, Inc. has a fifty-two week low of $236.73 and a fifty-two week high of $396.23.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%. The firm had revenue of $651.00 million during the quarter, compared to the consensus estimate of $623.99 million. During the same period last year, the company earned $2.61 earnings per share. The company’s revenue for the quarter was down .1% on a year-over-year basis. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.28 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Citigroup raised their price objective on Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Wells Fargo & Company upped their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday. Finally, Royal Bank Of Canada lifted their price target on Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $343.33.

Get Our Latest Stock Report on BIO

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc is a global life science research and clinical diagnostics company headquartered in Hercules, California. Founded in 1952, the company develops, manufactures and sells products that support scientific research, biotechnology production, medical testing and quality assurance.

Its Life Science segment provides instruments, reagents, consumables and software used in areas such as genomics, proteomics, cell biology, digital PCR, electrophoresis, chromatography and biopharmaceutical manufacturing.

Read More

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).